Patient perspective on follow-up care for bladder cancer: experiences with cystoscopy and acceptance of AI-supported urine cytology

Patient perspective on follow-up care for bladder cancer: experiences with cystoscopy and acceptance of AI-supported urine cytology - PACIFIC-BC (Patient Acceptance of Cystoscopy and Intelligent Follow-up in Bladder Cancer)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039302

Enrollment

200

Registered

2026-02-17

Start date

2026-02-23

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C67

Interventions

Group 1: Patients with a confirmed diagnosis of bladder cancer are surveyed once using a standardized questionnaire about their experiences with follow-up care (cystoscopy) and their attitudes toward

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of bladder cancer, membership in a support group or contact through such a group, sufficient knowledge of German, capacity to give consent

Exclusion criteria

Exclusion criteria: Incapacity to give consent, insufficient knowledge of German, no diagnosis of bladder cancer

Design outcomes

Primary

Measure	Time frame
1. Quantitative assessment of patient-reported distress during cystoscopy, including various dimensions of distress (e.g., pain during/after the examination, burning sensation when urinating, shame, anxiety/stress before the appointment, concern about the results, feeling of loss of control/helplessness, organizational effort); using a visual analog scale (VAS, 0–10) 2. Assessment of the importance of research into non-invasive alternatives to cystoscopy from the patient's perspective; recorded using a five-point Likert scale from unimportant to very important	—

Measure

Time frame

1. Quantitative assessment of patient-reported distress during cystoscopy, including various dimensions of distress (e.g., pain during/after the examination, burning sensation when urinating, shame, anxiety/stress before the appointment, concern about the results, feeling of loss of control/helplessness, organizational effort); using a visual analog scale (VAS, 0–10) 2. Assessment of the importance of research into non-invasive alternatives to cystoscopy from the patient's perspective; recorded using a five-point Likert scale from unimportant to very important

—

Secondary

Measure	Time frame
1.Rate of adverse side effects (urinary tract infections, bleeding, persistent pain among respondents) following cystoscopy; recorded using relative frequencies 2. Survey of examination conditions: percentage of rigid vs. flexible cystoscopies and percentage of different forms of anesthesia 3. Rate of psychological stress (sleep disorders, depression) in the context of follow-up care; recorded using relative frequencies 4. Participants' confidence in AI-supported urine cytology compared to evaluation by a physician (preference indicated: physician alone vs. AI alone vs. combination); recorded once using a questionnaire 5. Collection of additional follow-up care-related information, e.g., percentage of wearers of various urinary tract devices, percentage of patients who were offered a structured smoking cessation program	—

Measure

Time frame

1.Rate of adverse side effects (urinary tract infections, bleeding, persistent pain among respondents) following cystoscopy; recorded using relative frequencies 2. Survey of examination conditions: percentage of rigid vs. flexible cystoscopies and percentage of different forms of anesthesia 3. Rate of psychological stress (sleep disorders, depression) in the context of follow-up care; recorded using relative frequencies 4. Participants' confidence in AI-supported urine cytology compared to evaluation by a physician (preference indicated: physician alone vs. AI alone vs. combination); recorded once using a questionnaire 5. Collection of additional follow-up care-related information, e.g., percentage of wearers of various urinary tract devices, percentage of patients who were offered a structured smoking cessation program

—

Countries

Germany

Contacts

Public ContactGloria Baumann

Klinik für Urologie und Urochirurgie Universitätsmedizin Mannheim

gloria.baumann@dkfz-heidelberg.de+491703470078

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026